AKESO(09926),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

09926 AKESO

Market Closed 05-15 16:09:05

120.200

-3.600

-2.91%

High122.900	Low118.100	Vol7.89M
Open122.500	D1 Closing123.800	Amplitude3.88%
Mkt Cap110.70B	Tradable Cap110.70B	Total Shares921.00M
T/O947.72M	T/O Rate0.86%	Tradable Shares921.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"09926","market":"HK","secType":"STK","nameCN":"AKESO","latestPrice":120.2,"timestamp":1778832545008,"preClose":123.8,"halted":0,"volume":7893253,"delay":0,"changeRate":-0.0290791599353796,"floatShares":921000000,"shares":921000000,"eps":-1.232771,"marketStatus":"Market Closed","change":-3.6,"latestTime":"05-15 16:09:05","open":122.5,"high":122.9,"low":118.1,"amount":947718977,"amplitude":0.038772,"askPrice":120.3,"askSize":14000,"bidPrice":120.2,"bidSize":11000,"shortable":3,"etf":0,"ttmEps":-1.37184,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1779067800000},"marketStatusCode":7,"adr":0,"listingDate":1587657600000,"exchange":"SEHK","adjPreClose":123.8,"openAndCloseTimeList":[[1778808600000,1778817600000],[1778821200000,1778832000000]],"volumeRatio":1.35629102634098,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"AKS.HK","impliedVol":0.6639,"impliedVolPercentile":0.8205},"requestUrl":"/m/hq/s/09926","defaultTab":"news","newsList":[{"id":"2635494709","title":"Phase Ii Data From a Randomized Double-Blind Trial of Ligufalimab (Anti-Cd47) Combination Therapy in Frontline Aml Published at Eha 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2635494709","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635494709?lang=en_us&edition=fundamental","pubTime":"2026-05-15 15:44","pubTimestamp":1778831053,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nTUA93SMFQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0540923850.HKD","BK1161","LU0348766576.USD","LU0348767384.USD","LU1961090484.USD","LU0417516738.SGD","LU0348783233.USD","LU0417516571.SGD","IE00B5MMRT66.SGD","LU2476274308.USD","LU0634319403.HKD","LU2488822045.USD","LU0348735423.USD","LU0561508036.HKD","LU2778985437.USD","IE00BPRC5H50.USD","LU2399975544.HKD","09926","IE00B543WZ88.USD","LU0348827113.USD","LU2476274720.SGD","BK1574","LU0348784397.USD","LU1720050803.USD","LU1794554557.SGD","LU0348825331.USD","LU0417516902.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104056034","title":"AKESO Maintains Stable Capital Structure in April; Issued Shares Steady at 921.14 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1104056034","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1104056034?lang=en_us&edition=fundamental","pubTime":"2026-05-06 16:23","pubTimestamp":1778055785,"startTime":"0","endTime":"0","summary":"Akeso, Inc. reported no changes to its share capital during April 2026, keeping both authorised and issued share counts intact. The company’s authorised share capital remained at 5.00 billion...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129022352","title":"Stock Track | AKESO Soars 5.32% in Morning Session as Market Reassesses Ivonescimab Trial Interim Results","url":"https://stock-news.laohu8.com/highlight/detail?id=1129022352","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1129022352?lang=en_us&edition=fundamental","pubTime":"2026-05-06 10:49","pubTimestamp":1778035771,"startTime":"0","endTime":"0","summary":"AKESO's stock price surged 5.32% during the morning trading session, marking a significant rebound for the biopharmaceutical company.The upward movement represents a recovery following a previous...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190831371","title":"AKESO Shares Climb Over 5% in Morning Session as Institutions Remain Confident in Ivonescimab's Potential Against Keytruda","url":"https://stock-news.laohu8.com/highlight/detail?id=1190831371","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1190831371?lang=en_us&edition=fundamental","pubTime":"2026-05-06 09:55","pubTimestamp":1778032516,"startTime":"0","endTime":"0","summary":"AKESO (09926) saw its shares rise more than 5% during the morning trading session. At the time of writing, the stock was up 5.48%, trading at HK$134.8 with a turnover of HK$555 million. On the news...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1093756168.USD","LU1989772840.SGD","BK4559","LU2023250504.SGD","BK4585","LU0106261372.USD","LU1699723380.USD","LU1037948541.HKD","LU0348735423.USD","BK4007","LU0634319403.HKD","LU0980610538.SGD","LU0266013472.USD","LU2399975544.HKD","IE000M9KFDE8.USD","IE0009355771.USD","LU0234572021.USD","LU0477156953.USD","LU0417516902.SGD","IE00B2B36J28.USD","LU2106854487.HKD","LU1974910355.USD","LU1023059063.AUD","LU0208291251.USD","LU1116320901.HKD","LU0058720904.USD","LU2361045086.USD","SG9999014567.USD","IE00BFTCPJ56.SGD","IE00BN8TJ469.HKD","LU1291159041.SGD","LU1961090484.USD","IE00BJT1NW94.SGD","LU2491050154.USD","LU2360032135.SGD","LU0289739699.SGD","BK4534","LU0859254822.USD","LU0265550946.USD","LU0203345920.USD","LU0265550359.USD","LU0965509101.SGD","LU1934455863.HKD","LU2491049909.HKD","LU1035773651.USD","SG9999001176.SGD","LU0348767384.USD","SG9999001176.USD","LU0348783233.USD","LU0320765646.SGD","LU1934455194.USD","LU1585245621.USD","LU1037948897.HKD","SG9999002232.USD","LU1934455277.USD","LU1571399168.USD","IE0002141913.USD","LU2361044949.HKD","LU2488822045.USD","LU0211331839.USD","SG9999002224.SGD","LU0417516571.SGD","LU0238689110.USD","BK1161","IE00BSNM7G36.USD","LU2112291526.USD","LU2468319806.SGD","LU1061106388.HKD","LU1929549753.HKD","LU0561508036.HKD","09926","LU0098860793.USD","LU0861579265.USD","LU0942090050.USD","IE00B543WZ88.USD","LU1116320737.USD","LU0985320562.USD","LU1794554557.SGD","LU0122379950.USD","SGXZ57979304.SGD","LU1941712264.USD","SG9999014542.SGD","LU0070302665.USD","BK4516","LU0130517989.USD","LU0648001328.SGD","LU1057294990.SGD","LU2089984988.USD","SG9999013999.USD","IE00BJJMRZ35.SGD","LU2324357040.USD","IE00B1BXHZ80.USD","LU0203347892.USD","LU2357627491.SGD","LU1720050803.USD","LU0868494617.USD","LU2778985437.USD","LU1066051498.USD","LU0432979614.USD","IE00BBT3K403.USD","LU1066053197.SGD","LU0348766576.USD","BK4550","IE00BPRC5H50.USD","LU0006306889.USD","LU0417516738.SGD","LU1066051811.HKD","SG9999015341.SGD","IE00BLSP4452.SGD","LU0965509010.AUD","BK4533","LU0540923850.HKD","SG9999001440.SGD","LU1201861249.SGD","BK1574","LU0965509283.SGD","LU1989772923.USD","LU2461242641.AUD","LU2476274720.SGD","LU2491050071.SGD","LU0348827113.USD","IE00BLSP4239.USD","LU2125154935.USD","LU2476274308.USD","LU1093756325.SGD","IE00B4R5TH58.HKD","IE00B5MMRT66.SGD","LU0320765489.SGD","LU1983299246.USD","LU2361044865.SGD","SG9999015358.SGD","LU2023250843.SGD","LU0965508806.USD","LU1162221912.USD","LU1941712348.USD","LU0348825331.USD","LU0130102774.USD","BK4588","LU1430594728.SGD","LU1917777945.USD","SG9999014575.USD","LU1066051225.USD","LU0348784397.USD","LU2125154778.USD","LU1989771016.USD","SG9999014559.SGD","LU0868494708.USD","LU1069347547.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104766980","title":"Stock Track | Akeso Plummets 9.65% Intraday After Partner's Clinical Trial Disappointment","url":"https://stock-news.laohu8.com/highlight/detail?id=1104766980","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1104766980?lang=en_us&edition=fundamental","pubTime":"2026-05-04 09:38","pubTimestamp":1777858720,"startTime":"0","endTime":"0","summary":"Akeso's stock plummeted 9.65% during intraday trading on Monday, following negative news regarding a key clinical trial for a co-developed drug.The decline came after Akeso's overseas partner, Summit...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632696357","title":"3 Asian Stocks Estimated To Be Up To 31.8% Below Intrinsic Value","url":"https://stock-news.laohu8.com/highlight/detail?id=2632696357","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632696357?lang=en_us&edition=fundamental","pubTime":"2026-05-01 06:04","pubTimestamp":1777586671,"startTime":"0","endTime":"0","summary":"As global markets navigate geopolitical tensions and economic uncertainties, Asian equities have shown resilience, with some indices maintaining stability amid fluctuating conditions. In this environment, identifying undervalued stocks can offer opportunities for investors seeking to capitalize on potential market inefficiencies. Recognizing a good stock often involves assessing its intrinsic value relative to its current price, especially in regions like Asia where emerging economic trends...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/9612017-choice2-main-header/1585186662059","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9612017-choice2-main-header/1585186662059"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/tw/tech/twse-2383/elite-material-shares/news/3-asian-stocks-estimated-to-be-up-to-318-below-intrinsic-val","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/tw/tech/twse-2383/elite-material-shares/news/3-asian-stocks-estimated-to-be-up-to-318-below-intrinsic-val","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0348825331.USD","IE00B543WZ88.USD","LU1720050803.USD","LU0417516902.SGD","BK1161","LU2476274308.USD","LU0634319403.HKD","LU0348767384.USD","LU2476274720.SGD","BK1574","09926","IE00B5MMRT66.SGD","IE00BPRC5H50.USD","LU0417516571.SGD","LU2488822045.USD","LU0540923850.HKD","LU2399975544.HKD","LU0417516738.SGD","LU0348827113.USD","LU0348766576.USD","LU1794554557.SGD","LU1961090484.USD","LU0348784397.USD","LU2778985437.USD","LU0348735423.USD","LU0561508036.HKD","LU0348783233.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106640568","title":"AKESO（09926）2025年总收入达305.62亿元分（30.562亿元），双特异抗体商业化与研发并进，净亏损有所扩大","url":"https://stock-news.laohu8.com/highlight/detail?id=1106640568","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1106640568?lang=en_us&edition=fundamental","pubTime":"2026-04-29 23:30","pubTimestamp":1777476651,"startTime":"0","endTime":"0","summary":"根据AKESO（股票代码：09926）最新年度报告，2025年公司总收入达到人民币30.562亿元（即人民币3,056.2百万除以100得到30.562亿元），较2024年的21.239亿元（即人民币2,123.9百万除以100得到21.239亿元）同比增长43.9%。其中商业销售收入（扣除分销费用后）约为30.331亿元（3,033.1百万÷100），同比上升51.48%；许可收入为0.232亿...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"AKESO（09926）2025年总收入达305.62亿元分（30.562亿元），双特异抗体商业化与研发并进，净亏损有所扩大","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122936220","title":"Akeso reminds non-registered shareholders of switch to electronic corporate communications","url":"https://stock-news.laohu8.com/highlight/detail?id=1122936220","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1122936220?lang=en_us&edition=fundamental","pubTime":"2026-04-29 23:25","pubTimestamp":1777476336,"startTime":"0","endTime":"0","summary":"Akeso, Inc. issued a reminder on 29 April 2026 that it has fully adopted electronic dissemination for all future corporate communications—including annual and interim reports, meeting notices,...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631569545","title":"Akeso publishes 2025 ESG report","url":"https://stock-news.laohu8.com/highlight/detail?id=2631569545","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631569545?lang=en_us&edition=fundamental","pubTime":"2026-04-29 22:51","pubTimestamp":1777474304,"startTime":"0","endTime":"0","summary":"Akeso outlined 2025 ESG priorities after identifying 21 material issues, including clinical trial safety, product quality, data security, R&D innovation, business ethics.Anti-corruption and compliance training covered 3,752 employees with 99.8% participation; director participation was 66.7%.Company reported no corruption-related lawsuits or legal disputes settled or accepted during 2025.Akeso reported 1,085 cumulative patent applications with 218 granted; trademark applications totaled 534 with 434 registered.Supply chain controls included 41 on-site supplier audits with 97.56% pass rate; supplier base totaled 469 in China, 47 outside China.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akeso Inc. published the original content used ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nNDL873qM1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BPRC5H50.USD","IE00B5MMRT66.SGD","LU0417516571.SGD","LU0348827113.USD","LU1794554557.SGD","LU0348783233.USD","LU0634319403.HKD","LU1961090484.USD","LU0348766576.USD","LU0417516738.SGD","LU0540923850.HKD","LU0417516902.SGD","LU2476274308.USD","LU0348825331.USD","LU1720050803.USD","09926","LU2488822045.USD","LU0348735423.USD","LU0348767384.USD","LU2476274720.SGD","LU0348784397.USD","IE00B543WZ88.USD","LU0561508036.HKD","LU2399975544.HKD","BK1161","BK1574","LU2778985437.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630373008","title":"Akeso says Phase III HARMONi-2 trial shows ivonescimab beats pembrolizumab on PFS","url":"https://stock-news.laohu8.com/highlight/detail?id=2630373008","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630373008?lang=en_us&edition=fundamental","pubTime":"2026-04-28 16:08","pubTimestamp":1777363732,"startTime":"0","endTime":"0","summary":"Akeso reported April 28, 2026 that ivonescimab gained upgraded recommendations in 2026 CSCO guideline for non-small cell lung cancer, strengthening its positioning in first-line treatment.Phase III HARMONi-2 results were already presented in guideline update, supporting ivonescimab monotherapy as preferred option versus pembrolizumab in PD-L1-positive disease.Phase III HARMONi-6 results were cited as positive, supporting ivonescimab with chemotherapy in first-line squamous disease, with regulatory review ongoing for this use.Guideline update also maintained ivonescimab with chemotherapy as recommended option for EGFR-mutant disease following resistance, supporting broader commercial reach across treatment lines.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260428:nNDL3DXs5f:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0348783233.USD","LU0417516902.SGD","LU0348827113.USD","LU2399975544.HKD","LU2488822045.USD","IE00B5MMRT66.SGD","LU0348735423.USD","LU2476274308.USD","LU1720050803.USD","LU0561508036.HKD","LU0348767384.USD","LU1794554557.SGD","LU0417516738.SGD","IE00BPRC5H50.USD","LU0540923850.HKD","LU1961090484.USD","BK1574","LU0417516571.SGD","LU0348784397.USD","LU2476274720.SGD","LU0634319403.HKD","BK1161","LU0348825331.USD","09926","IE00B543WZ88.USD","LU0348766576.USD","LU2778985437.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185557523","title":"AKESO's Cadonilimab Demonstrates Counter-Seasonal Quarterly Growth, Says Bank of America","url":"https://stock-news.laohu8.com/highlight/detail?id=1185557523","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1185557523?lang=en_us&edition=fundamental","pubTime":"2026-04-28 15:08","pubTimestamp":1777360098,"startTime":"0","endTime":"0","summary":"Bank of America Securities has released a research report indicating that AKESO's (09926) cadonilimab achieved quarter-over-quarter growth against seasonal trends. In February, the sample drug sales...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0417516571.SGD","LU2778985437.USD","IE00BPRC5H50.USD","LU0417516902.SGD","LU2476274308.USD","BK1161","IE00B5MMRT66.SGD","09926","LU1961090484.USD","LU0561508036.HKD","LU0540923850.HKD","LU2488822045.USD","LU0348827113.USD","LU0348783233.USD","BK1574","LU2476274720.SGD","LU0348766576.USD","LU2399975544.HKD","LU0348735423.USD","LU0348825331.USD","LU0348784397.USD","LU0348767384.USD","LU1794554557.SGD","IE00B543WZ88.USD","LU0634319403.HKD","LU0417516738.SGD","161027","LU1720050803.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125463972","title":"Stock Track | AKESO Soars 5.24% Intraday on Positive Phase II Pancreatic Cancer Trial Data","url":"https://stock-news.laohu8.com/highlight/detail?id=1125463972","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1125463972?lang=en_us&edition=fundamental","pubTime":"2026-04-27 13:03","pubTimestamp":1777266211,"startTime":"0","endTime":"0","summary":"AKESO's stock surged 5.24% during intraday trading on Monday, marking a significant upward movement for the biopharmaceutical company.The sharp rise appears driven by continued positive investor...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630800051","title":"Akeso (SEHK:9926) Valuation Check After Positive Cadonilimab Phase II Data In Advanced Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2630800051","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630800051?lang=en_us&edition=fundamental","pubTime":"2026-04-26 06:09","pubTimestamp":1777154986,"startTime":"0","endTime":"0","summary":"Akeso (SEHK:9926) is back in focus after presenting positive Phase II COMPASSION-26 data at the 2026 AACR meeting, highlighting cadonilimab plus chemotherapy in advanced pancreatic ductal adenocarcinoma.\nSee our latest analysis for Akeso.\nAkeso's share price is trading at HK$131.6 after a 16.15% year-to-date share price return, with recent clinical updates arriving alongside a 12.96% 90-day share price gain and a very large 3-year total shareholder return of 207.12%. This suggests momentum...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9926/akeso-shares/news/akeso-sehk9926-valuation-check-after-positive-cadonilimab-ph","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9926/akeso-shares/news/akeso-sehk9926-valuation-check-after-positive-cadonilimab-ph","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0348827113.USD","IE00B5MMRT66.SGD","LU2476274308.USD","BK1574","LU2778985437.USD","IE00B19Z4B17.USD","LU0348766576.USD","BK4157","LU0348825331.USD","BK1161","LU0417516738.SGD","LU0634319403.HKD","LU0348783233.USD","LU0348767384.USD","LU0561508036.HKD","LU0348735423.USD","IE00BPRC5H50.USD","IE00B7SZL793.SGD","LU2476274720.SGD","LU2488822045.USD","LU1720050803.USD","LU0540923850.HKD","LU2399975544.HKD","LU0417516571.SGD","LU1815336091.USD","IE00B543WZ88.USD","LU0757428866.USD","LU0348784397.USD","IE0031619046.USD","IE00B66KJ199.SGD","LU1794554557.SGD","09926","AEIS","LU0417516902.SGD","LU1961090484.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629883254","title":"BUZZ-HK-listed Akeso slides to 3-week low","url":"https://stock-news.laohu8.com/highlight/detail?id=2629883254","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629883254?lang=en_us&edition=fundamental","pubTime":"2026-04-23 15:50","pubTimestamp":1776930641,"startTime":"0","endTime":"0","summary":"BUZZ-HK-listed Akeso slides to 3-week low** Shares of antibody drugs developer Akeso Inc 9926.HK plunge 12.9% to HK$130, their lowest level since March 31** Stock on track for the biggest one-day pct decline since April 7, 2025; top pct loser in Hang Seng Biotech Index .HSBIO, which is down 4.1% ** Stock up nearly 15% in the last three weeks** \"Think it should be profit taking after Akeso confirmed LBA  in ASCO ,\" said Cui Cui, head of Asia Healthcare at Jefferies ** Onshore investors had been betting on positive data since early March, and the LBA suggests potentially positive results but inline with market expectations, Cui says** Nomura keeps \"neutral\" rating and lifts target price to HK$142.75 from HK$112.73, saying Akeso's ivonescimab is set to report overall survival  data from HARMONi-6 trial at ASCO annual meeting from May 29 to June 2 ** \"The results should be good,\" Nomura wrote, adding the LBA in the plenary-session status suggests that the OS data is most likely to be posit","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260423:nL1N4160BT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0348784397.USD","LU1794554557.SGD","IE00BPRC5H50.USD","LU0540923850.HKD","09926","LU2399975544.HKD","LU0348825331.USD","LU0417516738.SGD","LU0348735423.USD","LU0348767384.USD","LU0348827113.USD","BK1574","LU1961090484.USD","LU0634319403.HKD","LU0348783233.USD","LU0561508036.HKD","LU2476274308.USD","BK1161","IE00B5MMRT66.SGD","LU0348766576.USD","LU2778985437.USD","LU0417516902.SGD","LU2476274720.SGD","IE00B543WZ88.USD","LU1720050803.USD","LU2488822045.USD","LU0417516571.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165196464","title":"HK Biotech Stocks Fell. Akeso Down 12%; Remegen, Zai Lab, KeyMed And Junshi Down 7%; Lepu And Innocare Down 6%","url":"https://stock-news.laohu8.com/highlight/detail?id=1165196464","media":"Tiger Newspress","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1165196464?lang=en_us&edition=fundamental","pubTime":"2026-04-23 11:32","pubTimestamp":1776915127,"startTime":"0","endTime":"0","summary":"HK biotech stocks fell. Akeso down 12%; Remegen, Zai Lab, KeyMed and Junshi down 7%; Lepu and Innocare down 6%.","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"330240692f324d079ccf839d9e4180bf","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02359","02137","02162","09966","02268","01672","06978","03759","03347","02269","09926","06606","09688","09995","09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184360495","title":"Stock Track | AKESO Plummets 5.69% Intraday as Fundamental Concerns Overshadow Positive Clinical Data","url":"https://stock-news.laohu8.com/highlight/detail?id=1184360495","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1184360495?lang=en_us&edition=fundamental","pubTime":"2026-04-23 09:40","pubTimestamp":1776908440,"startTime":"0","endTime":"0","summary":"AKESO's stock plummeted 5.69% during intraday trading, giving back gains from the previous session.The sharp decline comes despite the recent release of positive Phase II clinical data for its...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629146045","title":"Is It Too Late To Consider Akeso (SEHK:9926) After Strong Five Year Share Gains?","url":"https://stock-news.laohu8.com/highlight/detail?id=2629146045","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629146045?lang=en_us&edition=fundamental","pubTime":"2026-04-22 19:20","pubTimestamp":1776856803,"startTime":"0","endTime":"0","summary":"If you are wondering whether Akeso shares still offer value after a strong run, the numbers behind the current price deserve a closer look.\nAt a last close of HK$149.30, Akeso has delivered returns of 1.3% over 7 days, 33.2% over 30 days, 31.8% year to date and 60.7% over 1 year, with a very large 3 year gain and 173.2% over 5 years.\nThese moves have put Akeso on the radar of investors trying to understand what is already priced in and what may still be up for grabs. Recent coverage has...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9926/akeso-shares/news/is-it-too-late-to-consider-akeso-sehk9926-after-strong-five","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9926/akeso-shares/news/is-it-too-late-to-consider-akeso-sehk9926-after-strong-five","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["IE00B5MMRT66.SGD","09926","LU0348784397.USD","LU0348735423.USD","LU2399975544.HKD","LU2476274720.SGD","LU1961090484.USD","LU0417516902.SGD","LU1794554557.SGD","LU0417516738.SGD","BK1161","BK1574","IE00BPRC5H50.USD","DCF","LU2778985437.USD","LU0348766576.USD","LU2476274308.USD","IE00B543WZ88.USD","LU0348827113.USD","LU0634319403.HKD","LU0540923850.HKD","LU0348767384.USD","LU0561508036.HKD","LU2488822045.USD","LU0348825331.USD","LU0348783233.USD","LU1720050803.USD","LU0417516571.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101728190","title":"AKESO Shares Climb Nearly 3% on Positive Phase II Data for Cadonilimab Combo in Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=1101728190","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1101728190?lang=en_us&edition=fundamental","pubTime":"2026-04-22 10:36","pubTimestamp":1776825408,"startTime":"0","endTime":"0","summary":"AKESO (09926) saw its shares rise by nearly 3%. As of the time of writing, the stock was up 2.66%, trading at HK$150.6 with a turnover of HK$613 million. The increase follows the company's...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU2476274308.USD","IE00B5MMRT66.SGD","BK1161","LU2488822045.USD","IE00BPRC5H50.USD","LU2778985437.USD","LU2399975544.HKD","LU0348784397.USD","LU0348827113.USD","LU1961090484.USD","LU0417516738.SGD","LU0348825331.USD","LU2476274720.SGD","VXUS","LU0348735423.USD","LU0348767384.USD","09926","LU1720050803.USD","BK4588","LU0540923850.HKD","LU0348766576.USD","LU1794554557.SGD","LU0634319403.HKD","LU0417516902.SGD","LU0417516571.SGD","LU0561508036.HKD","IE00B543WZ88.USD","BK1574","LU0348783233.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629706348","title":"Akeso says cadonilimab-chemo extends OS past 23 months in phase 2 pancreatic cancer trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2629706348","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629706348?lang=en_us&edition=fundamental","pubTime":"2026-04-21 10:54","pubTimestamp":1776740090,"startTime":"0","endTime":"0","summary":"Akeso reported Phase II COMPASSION-26 results for cadonilimab with chemotherapy in first-line advanced pancreatic cancer, already presented at AACR 2026.Data showed improved survival outcomes, with strongest benefit in locally advanced disease.Study also indicated broad tumor control across overall population, with similar response patterns in locally advanced and metastatic patients.Safety profile remained manageable, with no new safety concerns flagged.Update reinforces Akeso strategy to expand cadonilimab use into hard-to-treat tumors, supporting its longer-term growth outlook in oncology immunotherapy.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260421:nNDL62fwjK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","LU2488822045.USD","LU0634319403.HKD","LU0417516738.SGD","BK1574","LU2476274308.USD","LU2399975544.HKD","LU0348783233.USD","LU2476274720.SGD","LU2778985437.USD","IE00B543WZ88.USD","LU0348735423.USD","IE00B5MMRT66.SGD","09926","LU1794554557.SGD","LU1961090484.USD","LU0348766576.USD","LU0561508036.HKD","LU0348784397.USD","LU0348767384.USD","LU1720050803.USD","LU0417516571.SGD","LU0417516902.SGD","LU0540923850.HKD","IE00BPRC5H50.USD","LU0348827113.USD","LU0348825331.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124678664","title":"China International Capital Corporation: National Policy Optimizes Initial Pricing Mechanism for Innovative Drugs, Pharmaceutical Sector Set for High-Quality Development","url":"https://stock-news.laohu8.com/highlight/detail?id=1124678664","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1124678664?lang=en_us&edition=fundamental","pubTime":"2026-04-16 14:39","pubTimestamp":1776321543,"startTime":"0","endTime":"0","summary":"China International Capital Corporation (CICC) has released a research report stating that on April 14th, the General Office of the State Council issued the \"Several Opinions on Improving the Drug...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0348784397.USD","BK1583","01276","LU1303224171.USD","06978","LU0307460666.USD","HK0000252160.HKD","06160","LU0359202008.SGD","LU0588546209.SGD","LU2097828805.USD","LU2476274720.SGD","159992","LU0348767384.USD","LU1023057109.AUD","HK0000165453.HKD","LU0348825331.USD","BK1574","LU1794554557.SGD","BK1191","01801","HK0000500386.USD","LU2097828474.EUR","LU2328871848.SGD","LU2778985437.USD","LU1251922891.USD","LU0196878994.USD","HK0000252152.HKD","LU1961090484.USD","LU1720050803.USD","LU0417516738.SGD","LU1770034418.SGD","IE00B5MMRT66.SGD","LU1719994722.HKD","LU0348827113.USD","LU2097828714.EUR","LU2488822045.USD","IE00BPRC5H50.USD","LU2476274308.USD","LU2242644610.SGD","09606","LU0502904849.HKD","LU0348735423.USD","LU0359201612.USD","LU0540923850.HKD","IPOS","06990","LU0634319403.HKD","LU2097828631.EUR","LU0348766576.USD","LU0348783233.USD","LU0455707207.USD","LU0359201885.HKD","LU0417516571.SGD","LU0417516902.SGD","BK1500","BK1161","09926","BK1589","IE00B543WZ88.USD","LU0561508036.HKD","LU2399975544.HKD","LU2097828557.USD","LU2543165471.USD","LU1969619763.USD","BK1588"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.akesobio.com","stockEarnings":[{"period":"1week","weight":-0.103},{"period":"1month","weight":-0.1845},{"period":"3month","weight":0.1415},{"period":"6month","weight":0.0118},{"period":"1year","weight":0.4785},{"period":"ytd","weight":0.0637}],"compareEarnings":[{"period":"1week","weight":-0.0163},{"period":"1month","weight":0.0006},{"period":"3month","weight":-0.0227},{"period":"6month","weight":-0.0229},{"period":"1year","weight":0.107},{"period":"ytd","weight":0.013}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Akeso Inc is an investment holding company dedicated to the research, development, manufacturing and commercialization of antibody drugs that are affordable to patients worldwide. The Company’s programs covering the therapeutic areas of oncology, autoimmune and metabolic diseases. The Company's products mainly include cadonilimab (PD-1/CTLA-4), ivonescimab (PD-1/VEGF), Ligufalimab (AK117, CD47), Pulocimab (AK109, VEGFR-2), ANNIKO (penpulimab, PD-1), and tagitanlimab (PD-L1) used in oncology fields as well as ebronucimab (PCSK9), ebdarokimab (IL-12/IL-23), and Gumokimab (AK111, IL-17) used in metabolic and autoimmune therapeutic fields.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.003338},{"month":2,"riseRate":0.333333,"avgChangeRate":0.019031},{"month":3,"riseRate":0.5,"avgChangeRate":0.006875},{"month":4,"riseRate":0.833333,"avgChangeRate":0.041517},{"month":5,"riseRate":0.285714,"avgChangeRate":-0.019096},{"month":6,"riseRate":0.666667,"avgChangeRate":0.133235},{"month":7,"riseRate":0.5,"avgChangeRate":0.087867},{"month":8,"riseRate":0.5,"avgChangeRate":-0.007754},{"month":9,"riseRate":0.5,"avgChangeRate":0.036209},{"month":10,"riseRate":0.5,"avgChangeRate":0.046029},{"month":11,"riseRate":1,"avgChangeRate":0.102206},{"month":12,"riseRate":0.333333,"avgChangeRate":0.028279}],"exchange":"SEHK","name":"AKESO","nameEN":"AKESO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"AKESO(09926),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest AKESO(09926) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"AKESO,09926,AKESO股票,AKESO股票老虎,AKESO股票老虎国际,AKESO行情,AKESO股票行情,AKESO股价,AKESO股市,AKESO股票价格,AKESO股票交易,AKESO股票购买,AKESO股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"AKESO(09926),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest AKESO(09926) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}